GAP President John Dwyer wrote a piece in The Hill urging Congress to ensure research centers involved in Alzheimer’s clinical trials will have access to COVID-19 relief funds. COVID-19 has had a devastating impact on clinical trials and the medical research infrastructure that scientists depend upon to develop new drugs for Alzheimer’s and all the diseases we fear most. Without action, […]
Washington D.C. (July 9, 2020) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement regarding Biogen’s submission of its BLA application for Aducanumab with the FDA: “The Alzheimer’s research community is looking forward to a thoughtful review of Aducanumab and ideally, approval by the FDA. This application represents a singular […]
GAP President, John Dwyer, and GAP-Net site Great Lakes Clinical Trial spoke on the hit Alzheimer’s clinical trials have taken since COVID-19, and the losses that will come of it. After a frustrating 2019, Alzheimer’s researchers had reason to look forward to 2020 as a year of promise. Then the pandemic struck. “Last year, seven […]
Alice Bailey, a GAP Citizen Scientist Award nominee, wrote an Op-Ed piece in the Cambridge Chronicle about her experience as an Alzheimer’s patient and clinical trial volunteer. For many seniors, Alzheimer’s disease is surrounded by fear. Fear of the diagnosis can be so strong that some don’t want to learn about or talk about the […]
GAP President John Dwyer and GAP-Net Site Roper St. Francis Healthcare Research and Innovation Center in Charleston, South Carolina were featured on LIVE 5 WCSC News about the need for Alzheimer’s clinical trials to begin again. CHARLESTON, S.C. (WCSC) – Medical experts are worried that the COVID-19 pandemic has put delays on the search for […]
GAP President John Dwyer was quoted in AlzForum about the challenges and changes in Alzheimer’s clinical trials due to COVID-19. As Alzheimer’s research comes to, scientists are taking stock of the damage. In the academic world, the main cost was time (see Part 1 of this story). For most clinical studies, the damage was more tangible, with […]
GAP-Net Site, Brigham and Women’s Center for Alzheimer’s Research and Treatment, and GAP President, John Dwyer, were featured on Boston 25 News talking about how Alzheimer’s Clinical Trial volunteers and researchers are getting back on track after COVID-19 setbacks. The pandemic has put a pause on critical medical research. At Brigham and Women’s Hospital, some […]
GAP-Net site Great Lakes Clinical Trials in Chicago was featured in the Chicago Sun Times, where they discussed the difficulties of attracting Alzheimer’s disease trial participants during COVID-19. Jim Butler is receiving his monthly 45-minute infusion of drugs. What kind of drugs? He doesn’t know. Nor do the nurses administering them. Could be an experimental […]
In February, Stomping Ground Comedy Theater lead a workshop for caregivers about how to best interact with loved ones living with Alzheimer’s disease or dementia. They also attended our 2020 GAP-Net Site Optimization Conference at the end of February. Above Photo: Lindsey Goldsapp of Stomping Ground Comedy Theater leads a workshop for caregivers at the […]
June 2, 2020 The events that spurred the reaction around the country this weekend are painful reminders that injustice remains in our world. At the Global Alzheimer’s Platform Foundation® (GAP), we agree that monumental changes on local and national levels are necessary to address the issues plaguing Black and African American people in our country […]
This editorial was run in the Kelowna Daily Courier on May 20, 2020, on Clinical Trials Day during Clinical Trial Awareness Week. Dr. Kim Christie is the President of GAP-Net Site Okanagan Clinical Trials in Kelowna, British Columbia in Canada. Today is Clinical Trials Day, an observance commemorating the first controlled clinical trial conducted by […]
GAP-Net Site, the University of Kansas Alzheimer’s Disease Center’s (KU ADC) Outreach, Recruitment and Education Core earned the 2020 University of Kansas Medical Center Diversity, Equity and Inclusion Award. The University of Kansas Alzheimer’s Disease Center’s Outreach, Recruitment and Education Core earned the 2020 University of Kansas Medical Center Diversity, Equity and Inclusion Award. Presented […]
Dorene M. Rentz, PsyD, from GAP-Net site Brigham and Women’s Center for Alzheimer’s Research and Treatment, and Professor of Neurology at Harvard Medical School co-authored Costs of Early Stage Alzheimer’s Disease in the United States: Cross-Sectional Analysis of a Prospective Cohort Study (GERAS-US)1. You can find the study posted in The Journal of Alzheimer’s Disease […]
Global Alzheimer’s Platform Foundation president, John Dwyer, was quoted on how GAP is supporting GAP-Net sites during the COVID-19 pandemic, emphasizing the importance of safety and remote clinical trial testing. The coronavirus pandemic is upending not only life as we knew it, but Alzheimer’s clinical studies as well. In the United States, Europe, and Australia, […]
A participant might commit months or years to a drug trial, only to see it vanish overnight. On March 21, 2019, the staff at the Penn Memory Center in Philadelphia was scrambling to learn more about an early-morning announcement: Two pharmaceutical companies, Biogen and Eisai, would discontinue their clinical trial of a drug intended to […]
A site in the Global Alzheimer’s Platform Foundation’s network, ClinCloud Clinical Research, was featured on FOX35 Orlando on March 4, 2020 at 6pm. Click here to watch the segment. MAITLAND, Fla. – Researchers have been spending years trying to cure Alzheimer’s Disease. We’ve seen several medical breakthroughs in Central Florida, but they are still running into problems. They […]
This past week, the Global Alzheimer’s Platform Foundation, which works with a national network of clinical research centers, held its annual Site Optimization Conference in Orlando. The conference brings together the leaders of more than 80 clinical trial sites throughout the U.S. and Canada who work day in and day out to identify a cure […]
A Spanish translation of the article below can be found on Orlando Sentenial posted on February 27, 2020 by Ginayra Alvarado Villegas. According to statistics from the Alzheimer’s Association in the United States, every 65 seconds a person develops Alzheimer’s disease, a disease that has doctors and researchers conducting studies to develop a drug or […]
CHICAGO, Feb. 27, 2020 /PRNewswire/ — The number of commercially insured Americans age 30 to 64 diagnosed with early-onset dementia or Alzheimer’s disease increased by 200% from 2013 to 2017. The average age of a person living with either form of dementia is 49. The findings came from a new Blue Cross Blue Shield Association (BCBSA) report, “Early-Onset […]
At a pivotal time in Alzheimer’s research, the GAP Foundation and the Alzheimer’s Drug Discovery Foundation will connect funders with leading innovators Updated on March 26, 2020: The Global Alzheimer’s Platform Foundation (GAP) has announced it is postponing the GAP Innovation Summit that was to be held on May 5, 2020 with our partner, the […]
The Global Alzheimer’s Platform Foundation recognizes the impact that GAP-Net site Georgetown University Medical Center’s Memory Disorders Program has had on Alzheimer’s disease research. We congratulate them on their 20 years of dedication and service to the field. WASHINGTON (WJLA) — It’s estimated that one in 10 people 65 and over has Alzheimer’s disease. That’s nearly […]
The Global Alzheimer’s Platform Foundation is proud and honored to work with GAP Net site Butler Hospital Memory and Aging Program’s Dr. Stephen Salloway, who was named Rhode Island’s Man of the Year for 2019. It is the cruelest of diseases. It is the sixth leading cause of death in America. In the United States, […]
Three research volunteers given first ever national award for their essential role in combatting the greatest public health crisis for our society in this century Washington, DC (October 23, 2019) – Today, the Global Alzheimer’s Platform Foundation® (GAP) honors three Citizen Scientists® in recognition of the indispensable role clinical trial volunteers play in the fight […]
First disease-modifying drug in 16 years to be submitted for FDA approval in 2020 ***John Dwyer is available for comment today live from the National Alzheimer’s Summit in Washington, D.C.*** Washington, DC (October 22, 2019) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement on the announcement today […]